Business
Appointment of Sath Nirmalananthan to the Board
Appointment of Sath Nirmalananthan to the Board.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n14 March 2024\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \n \nAppointment of Sath Nirmalananthan to the Board of Directors\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that Sath Nirmalananthan, Chief Financial Officer, has been appointed to the Company's Board of Directors (the \"Board\") with immediate effect.\n \nSath was appointed as the Company's Chief Financial Officer on 29 August 2023, having previously served as Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. He brings more than 15 years' experience in the healthcare sector, and has held roles at FTSE and NASDAQ listed companies, including Reckitt and BTG. Prior to this Sath held positions in investment banking at Nomura, and at KPMG. Sath is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales (ICAEW), and sits as a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR). He was awarded a BSc in Pharmacology from King's College, London.\n \nDr Jean-Michel Cosséry, Non-Executive Chairman of Scancell, commented: \"Since joining Scancell in August last year, Sath has brought considerable experience and expertise to the role, overseeing our successful £12 million fundraise from new and existing investors. Our focus remains on progressing SCIB1 and Modi-1 through the clinic whilst also actively seeking out-licensing, collaborations, and partnerships to accelerate the development and commercialisation of our products and platforms. Working closely with the Board, and Executive team, Sath will be instrumental in driving us towards realising the potential of these treatments for patients, while creating and delivering significant long-term value for our shareholders.\"\n \nCommenting on his new appointment, Sath Nirmalananthan, Chief Financial Officer and Director of Scancell, said: \"I am proud to take on this expanded role as a member of the Board, and I look forward to working with my fellow Board members and the wider team to deliver our goals for 2024 and beyond. This is an exciting time to be part of Scancell, as we continue to build significant momentum a...